CC-122 induces IFN-regulated proteins. (A) OCI-LY10 cells were treated with CC-122 (1 μM) for 18 hours, and gene expression profiling was performed. Gene set enrichment analysis REACTOME_INTERFERON_ALPHA_BETA_SIGNALING enrichment plot is shown for a category identified as positively enriched with CC-122 treatment in OCI-LY10 cells. False discovery rate = 0.001335. (B) DLBCL cells were treated with DMSO or CC-122 (0.1-10 μM) for 72 hours. Cell lysates were separated by SDS-PAGE, and levels of Aiolos, Ikaros, IRF7, DDX58, IFIT3, IRF4, and β-actin were assessed. (C) WSU-DLCL2 xenograft tumor samples were harvested 24 hours after dosing with either vehicle or CC-122 (30 mg/kg; top panel). Representative fields of FFPE samples from a non-GCB R/R-DLBCL patients administered with 3 mg of CC-122 daily (bottom). Screening and cycle 1 day 15 biopsies were obtained. Tissues were then subjected to FFPE IHC for IRF7. (D) OCI-LY10 and Karpas 422 cells were treated with DMSO or CC-122 (1-10 μM) for 72 hours, supernatants were harvested, and IFN-α and IFN-γ expression was measured by ELISA. A control standard curve of 10 000 pg/mL IFN-α or IFN-γ with fivefold serial dilutions was also determined. Data shown are the mean of 2 independent experiments tested in triplicate (±SD). (E) Inducible luciferase or Aiolos shRNA Karpas 422 cell lines were treated with 0 or 10 ng/mL of Dox for 3 days. Cell lysates were separated by SDS-PAGE, and levels of Aiolos, IRF7, DDX58, IFIT3, and β-actin were assessed. (F) Depiction of chromatin immunoprecipitation sequencing data from DF15 multiple myeloma cells showing Aiolos binding at the IRF7 promoter.